NCT02958358View on ClinicalTrials.gov

FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan

NAWithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions
Pulmonary Arterial Hypertension
Interventions
OTHER

CT imaging, functional PET imaging

Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Robert Scott Harris, M.D.

OTHER